Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 328 publications
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.
Journal: JCO oncology practice
Published: June 23, 2026
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma.
Journal: Journal for immunotherapy of cancer
Published: June 01, 2026
Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals.
Journal: JAMA dermatology
Published: May 27, 2026
Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.
Journal: Melanoma research
Published: May 19, 2026
Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report.
Journal: Frontiers in immunology
Published: April 24, 2026
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.
Journal: Oncotarget
Published: April 09, 2026
Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma.
Journal: Melanoma research
Published: April 08, 2026
Five-year survival with tebentafusp in metastatic uveal melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026
Translating ctDNA into cutaneous melanoma care: An international expert survey.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 13, 2026
Last Updated: 09/26/2026